Dana-Farber Cancer Institute oncologist Sara Tolaney, MD, MPH, explains treatment options for HR+/HER2- metastatic breast cancer, including aromatase inhibitors and CDK4/6 inhibitors.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.